271 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Aug 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2031
Next term end
132
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2033 · High confidence
Also notable
Ends Mar 2033 · High confidence
Also notable
Ends May 2034 · High confidence
Modified Polynucleotides
US 10,501,512
Cited by 178 later US patents, top 1% of utility patents granted in 2019 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides
US 10,501,513
Cited by 117 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Modified Polynucleotides Encoding Hepatitis a Virus Cellular Receptor 2
US 9,675,668
Cited by 173 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 16 to 30, 2026 · next Nov 16
- 6 fees due Dec 9 to 27, 2026 · next Dec 9
- 5 fees due Jan 2 to 28, 2027 · next Jan 2
- 9 fees due Feb 4 to 27, 2027 · next Feb 4
- 6 fees due Mar 5 to 26, 2027 · next Mar 5
- 8 fees due Apr 1 to 30, 2027 · next Apr 1
- 6 fees due May 5 to 26, 2027 · next May 5
- 12 fees due Jun 3 to 30, 2027 · next Jun 3
- 9 fees due Jul 2 to 28, 2027 · next Jul 2
- 8 fees due Aug 9 to 27, 2027 · next Aug 9
- 8 fees due Sep 1 to 29, 2027 · next Sep 1
- 2 fees due Oct 5 to 30, 2027 · next Oct 5
- 3 fees due Nov 10 to 14, 2027 · next Nov 10
Recent changes
- Nov 2Assignment recorded on 1 record: Dipiazza, Anthony T. and 4 others to ModernaTX, Inc. Recorded Nov 2, 2026, executed Oct 12, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76590, frame 130.
- 8 of the patents on this record were granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
What they patent
The 5 largest of its 132 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Combination PIV3/HMPV RNA Vaccines | 14 in force | to Oct 2036 |
| Compounds and Compositions for Intracellular Delivery of Therapeutic Agents | 10 in force | to Mar 2037 |
| Combinations of Mrnas Encoding Immune Modulating Polypeptides and Uses Thereof | 9 in force | to May 2037 |
| Engineered Nucleic Acids Encoding a Modified Erythropoietin and Their Expression | 9 in force | to Apr 2032 |
| Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease | 7 in force | to May 2033 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,822,663 | Engineered Nucleic Acids and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,181,319 | Engineered Nucleic Acids and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,447,164 | Engineered Nucleic Acids and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,937,233 | Engineered Nucleic Acids and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,657,295 | Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,701,965 | Engineered Nucleic Acids and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,064,959 | Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,334,328 | Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,710,200 | Engineered Nucleic Acids Encoding a Modified Erythropoietin and Their Expression In force · High confidence | In force | High confidence | |
| US 9,186,372 | Split Dose Administration In force · High confidence | In force | High confidence |
Also on record, not counted in the 271: 1 patent in force now held by others · 16 patents ended · 167 applications pending · 214 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.